Advances in Retinal Disease Treatments Based on Cell Therapy and Regenerative Medicine
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Methods".
Deadline for manuscript submissions: 15 May 2024 | Viewed by 1115
Special Issue Editor
Special Issue Information
Dear Colleagues,
Retinal diseases have long posed a significant challenge in the healthcare field, often resulting in irreversible vision loss and a diminished quality of life. However, recent advancements in cell therapy and regenerative medicine have offered a ray of hope for patients affected by these debilitating conditions. Cell therapy approaches, such as stem cell transplantation and retinal tissue engineering, have the potential to replace or repair damaged retinal cells, thereby restoring visual function. Researchers are exploring innovative strategies to promote tissue regeneration, enhance neuronal survival, and stimulate functional recovery within the retina. These cutting-edge techniques show immense promise for treating a range of retinal diseases, including age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. Ongoing research and clinical trials in the field of cell therapy and regenerative medicine are paving the way toward a brighter future for individuals grappling with retinal diseases, rekindling hope for sight restoration and improved quality of life.
In light of these remarkable advancements, this Special Issue aims to provide a comprehensive overview of the latest progress made in understanding and addressing retinal diseases. We seek to elucidate their underlying causes and subsequent consequences while exploring the potential of promising therapeutic strategies to halt or mitigate disease progression.
Your invaluable contributions to this Special Issue are eagerly anticipated.
Dr. Girish Kumar Srivastava
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- retinal diseases
- cell therapy
- regenerative medicine
- visual function restoration
- tissue regeneration
- neuronal survival
- promising therapeutic strategies
